BMS signs ADC development deal with Munich-based biotech worth more than $1B

BMS signs ADC development deal with Munich-based biotech worth more than $1B

Source: 
Medical Marketing and Media
snippet: 

BMS will have exclusive access to Tubulius’ proprietary P5 conjugation and Tubutecan platforms to develop customizable ADCs for treating cancer and solid tumors.